AAGILENT TECHNOLOGIES, INC.
- Analyst Upgrades
Stifel Maintains Buy on Agilent Technologies, Raises Price Target to $180
Stifel analyst Daniel Arias maintains Agilent Technologies with a Buy and raises the price target from $170 to $180. ...
- Analyst Upgrades
Citigroup Maintains Buy on Agilent Technologies, Raises Price Target to $190
Citigroup analyst Patrick Donnelly maintains Agilent Technologies with a Buy and raises the price target from $185 to $190. ...
- Analyst Upgrades
JP Morgan Maintains Overweight on Agilent Technologies, Raises Price Target to $190
JP Morgan analyst Casey Woodring maintains Agilent Technologies with a Overweight and raises the price target from $180 to $190. ...
- Analyst Upgrades
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $180
TD Cowen analyst Dan Brennan maintains Agilent Technologies with a Buy and raises the price target from $155 to $180. ...
- Analyst Upgrades
Bernstein Maintains Outperform on Agilent Technologies, Raises Price Target to $180
Bernstein analyst Eve Burstein maintains Agilent Technologies with a Outperform and raises the price target from $155 to $180. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Agilent Technologies, Raises Price Target to $185
RBC Capital analyst Dan Leonard maintains Agilent Technologies with a Outperform and raises the price target from $155 to $185. ...
- Analyst Upgrades
Evercore ISI Group Maintains Outperform on Agilent Technologies, Raises Price Target to $172
Evercore ISI Group analyst Vijay Kumar maintains Agilent Technologies with a Outperform and raises the price target from $148 to $172. ...
- BusinessWire
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
Delivers strong Q3 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Third-quarter fiscal year 2026 Revenue of $1.88 billion for the third ...
- Analyst Upgrades
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $175
Morgan Stanley analyst Kallum Titchmarsh maintains Agilent Technologies with a Overweight and raises the price target from $160 to $175. ...
- BusinessWire
Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
Eastern Institute of Technology professor recognized for advancing PFAS and emerging contaminant analysis Agilent Technologies Inc. (NYSE:A) today announced that the Eastern Institute of Technology, Ningbo has ...
- BusinessWire
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
Agilent Technologies Inc. (NYSE:A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the ...
- BusinessWire
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab) Agilent Technologies Inc. (NYSE:A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 ...
- BusinessWire
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Test enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has ...
- BusinessWire
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
Agilent Technologies Inc. (NYSE:A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to ...
- Analyst Upgrades
Evercore ISI Group Maintains Outperform on Agilent Technologies, Raises Price Target to $148
Evercore ISI Group analyst Vijay Kumar maintains Agilent Technologies with a Outperform and raises the price target from $144 to $148. ...
- BusinessWire
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
Simplifying label-free imaging analysis for more confident real-time cell analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module ...
- Analyst Upgrades
Bernstein Reinstates Outperform on Agilent Technologies, Announces $155 Price Target
Bernstein analyst Eve Burstein reinstates Agilent Technologies with a Outperform and announces $155 price target. ...
- GlobeNewswire
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Denver, CO and London, UK – 25 June 2026: Excellere Partners ("Excellere"), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP ...
- BusinessWire
Agilent Completes Acquisition of Biocare Medical
Highly complementary combination expands Agilent’s pathology portfolio and ability to serve customers across clinical and research settingsExpected to be accretive to Agilent’s top-line growth rate, margin profile and ...
- Analyst Upgrades
Piper Sandler Initiates Coverage On Agilent Technologies with Neutral Rating, Announces Price Target of $150
Piper Sandler analyst David Westenberg initiates coverage on Agilent Technologies with a Neutral rating and announces Price Target of $150. ...
- Analyst Upgrades
HSBC Maintains Buy on Agilent Technologies, Lowers Price Target to $165
HSBC analyst Sidharth Sahoo maintains Agilent Technologies with a Buy and lowers the price target from $180 to $165. ...
- BusinessWire
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Agilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, ...
- BusinessWire
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug ...
- Analyst Upgrades
B of A Securities Maintains Buy on Agilent Technologies, Raises Price Target to $155
B of A Securities analyst Derik De Bruin maintains Agilent Technologies with a Buy and raises the price target from $145 to $155. ...
- Analyst Upgrades
Wolfe Research Assumes Agilent Technologies at Peer Perform
Wolfe Research analyst Mike Polark assumes Agilent Technologies with a Peer Perform rating. ...